Continuous glucose monitoring for improving clinical outcome and quality of life in patients with diabetes and cancer

niversity of Leeds0 个研究点目标入组 202 人开始时间: 2024年7月17日最近更新: 2024年7月29日

适应症

试验速览

暂无简介。

•1. Aged >=18 years at the time of cancer diagnosis
•2. Biopsy-confirmed cancer of the colon, rectum, breast or lung. High-grade dysplasia is acceptable with unequivocal radiological evidence of invasive cancer
•3. Prior diagnosis of type 2 diabetes (T2D) recorded in primary or secondary care (diet-controlled or requiring hypoglycaemic therapies [including insulin])
•4. Cancer care being undertaken at, or managed by, the Leeds Teaching Hospitals NHS Trust, Calderdale and Huddersfield NHS Foundation Trust, Hull University Teaching Hospitals NHS Trust or Sheffield Teaching Hospitals NHS Foundation Trust
•5. Planned treatment for cancer includes chemotherapy

•1. Diabetes mellitus diagnosed during the course of active cancer treatment
•2. Any diabetes other than T2D
•3. Already using the FreeStyle Libre device
•4. Inability to give informed consent
•5. Known sensitivity to medical adhesives likely to result in an adverse reaction to the Libre device
•6. Deemed not suitable for inclusion by study investigators
•7. Previous treatment with chemotherapy within 6 months
•8. Have a pacemaker or any other neurostimulator

发起方

niversity of Leeds